Navigation Links
Yale team identifies key to potential new treatment for allergy-induced asthma
Date:5/18/2009

New Haven, Conn. In research that could lead to new asthma drugs, scientists at Yale School of Medicine, Hydra Biosciences of Cambridge, Massachusetts, and the University of California, San Francisco have discovered that a protein may be a trigger of allergy-induced asthma in mice. They also demonstrated how a drug known to reduce inflammatory and neuropathic pain may also inhibit asthma symptoms in mice. Their paper is published in the May 18-22 online Early Edition of the Proceedings of the National Academy of Sciences.

There has been a dramatic increase in the number of asthma cases reported in recent decades. Scientists know that asthma involves an immune response to inhaled allergens that results in inflammation, mucus secretion and bronchial constriction. But limitations of existing treatments aimed at the immune system suggest that additional physiological mechanisms may be involved in asthmatic inflammation.

The new study tracks the role of the ion channel protein TRPA1. While the exact function of TRPA1 in the airway inflammation of asthma is not completely understood, scientists do know from previous research that this ion channel protein is a sensor for chemical irritants such as cigarette smoke and certain chemicals that also trigger asthma. TRPA1 is found in airway nerves that mediate pain and irritation and trigger coughing and sneezing.

The researchers found that mice with no TRPA1 showed fewer signs of asthma. According to the paper's lead author, Sven-Eric Jordt, Ph.D., assistant professor of pharmacology at Yale School of Medicine, "When compared to normal mice, those lacking the gene for TRPA1 had greatly diminished inflammation, airway mucus and bronchoconstriction."

Furthermore, when the Yale-Hydra team administered a pharmacological agent, HC-030031, that is known to inhibit pain related to TRPA1, to mice with asthma, their symptoms were diminished. "Blocking TRPA1 may prevent the infiltration of the lung by the inflammatory cells responsible for asthma symptoms such as wheezing and mucus overproduction," Jordt explained.

The pharmacological agent observed in this study to diminish asthmatic symptoms in mice was identified by Hydra Biosciences. Yale's Sven-Eric Jordt serves on Hydra's scientific advisory board and receives consulting fees from Hydra. Several other members on the research team are employees of Hydra Biosciences and have a financial interest in the potential development of HC-030031 as a pharmacological treatment.


'/>"/>

Contact: Helen Dodson
helen.dodson@yale.edu
203-436-3984
Yale University
Source:Eurekalert

Related biology news :

1. UNC study identifies genetic cause of most common form of breast cancer
2. ISU researcher identifies key function in protein, cell transcription
3. CSHL-led team identifies key decision-point at which cells with broken DNA repair themselves or die
4. ISU researcher identifies protein that concentrates carbon dioxide in algae
5. Team identifies a molecular switch linking infectious disease and depression
6. UK researcher identifies just 8 patterns as the cause of all humor
7. Scripps research team identifies key molecules that inhibit viral production
8. Online collaboration identifies bacteria
9. International study identifies gene variants associated with early heart attack
10. MU researcher identifies possible genetic causes of borderline personality disorder
11. Stowers Institutes Baumann Lab identifies key step in maturation pathway of telomerase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
(Date:11/17/2016)... , Nov. 17, 2016  AIC announces that it has just released a new ... that require high-performance scale-out plus high speed data transfer storage solutions. Photo ... ... ... Setting up a high performance computing ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
Breaking Biology News(10 mins):
(Date:12/7/2016)... MA and Azusa, CA (PRWEB) , ... December ... ... provider of distributed wastewater treatment and resource recovery solutions for industrial facilities, today ... Company , will be the first to use Cambrian’s novel water-energy purchase agreement ...
(Date:12/7/2016)... , ... December 07, 2016 ... ... opening applications to an early access program for SmartBiome -- a novel ... with the simultaneous specific enrichment and detection of hundreds of different genes. ...
(Date:12/6/2016)... 2016 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... quarter and fiscal year ended September 30, 2016. ... , , ... and diagnostics company that develops and commercializes proprietary technologies and products ... Achieved revenues of $1.4 million more than tripling prior years ...
(Date:12/6/2016)... ... 06, 2016 , ... Discovering new clues to natural treatments that could allow ... in our brains. And searching for keys to our immune systems by studying parasite-resistant ... the 2017 Edith and Peter O’Donnell Awards by The Academy of ...
Breaking Biology Technology: